Abstract
Inhibition of thrombin receptor (PAR-1) is a promising therapeutic approach for the treatment of various cardiovascular disorders such as unstable angina, acute myocardial infarction, stroke, and restenosis. Since a PAR- 1 antagonist is specific for the cellulalr actions of thrombin, and does not interfere with fibrin generation, it is expected to have less bleeding liability than the currently available treatments. Several peptide and non-peptide PAR-1 antagonists with potent inhibition of platelet aggregation have been reported. Antithrombotic effect of a PAR-1 antibody has been demonstrated in a baboon thrombosis model and the antirestenosis property of a PAR-1 antagonist has been demonstrated in a rat model.
Keywords: G-Protein, thrombin receptor, acute myocardial infarction, baboon thrombosis model, restenosis
Current Topics in Medicinal Chemistry
Title: G-Protein Coupled Receptor Antagonists-1: Protease Activated Receptor-1 (PAR-1) Antagonists as Novel Cardiovascular Therapeutic Agents (Hot Topic: Structure and property Approaches in Recent Drug Discovery Guest Editor: Guo Zhu Zheng)
Volume: 3 Issue: 10
Author(s): Samuel Chackalamannil
Affiliation:
Keywords: G-Protein, thrombin receptor, acute myocardial infarction, baboon thrombosis model, restenosis
Abstract: Inhibition of thrombin receptor (PAR-1) is a promising therapeutic approach for the treatment of various cardiovascular disorders such as unstable angina, acute myocardial infarction, stroke, and restenosis. Since a PAR- 1 antagonist is specific for the cellulalr actions of thrombin, and does not interfere with fibrin generation, it is expected to have less bleeding liability than the currently available treatments. Several peptide and non-peptide PAR-1 antagonists with potent inhibition of platelet aggregation have been reported. Antithrombotic effect of a PAR-1 antibody has been demonstrated in a baboon thrombosis model and the antirestenosis property of a PAR-1 antagonist has been demonstrated in a rat model.
Export Options
About this article
Cite this article as:
Chackalamannil Samuel, G-Protein Coupled Receptor Antagonists-1: Protease Activated Receptor-1 (PAR-1) Antagonists as Novel Cardiovascular Therapeutic Agents (Hot Topic: Structure and property Approaches in Recent Drug Discovery Guest Editor: Guo Zhu Zheng), Current Topics in Medicinal Chemistry 2003; 3 (10) . https://dx.doi.org/10.2174/1568026033452122
DOI https://dx.doi.org/10.2174/1568026033452122 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
What is the Role of Cangrelor in Patients Undergoing PCI?
Current Vascular Pharmacology Unexpected Effects of Acetylcholine Precursors on Pilocarpine Seizure- Induced Neuronal Death
Current Neuropharmacology Need for Nutritious Convenience Foods for the Elderly Population: A Review
Current Nutrition & Food Science Editorial (Thematic Issue: Antihypertensive Treatment in the Elderly)
Cardiovascular & Hematological Agents in Medicinal Chemistry The mir-221/222 Cluster is a Key Player in Vascular Biology via the Fine-Tuning of Endothelial Cell Physiology
Current Vascular Pharmacology Increased Rates of Coronary Artery Calcium Score in Patients with Non - Functioning Adrenal Incidentaloma
Endocrine, Metabolic & Immune Disorders - Drug Targets Nanocarriers in Improved Heparin Delivery: Recent Updates
Current Pharmaceutical Design Immunomodulator Activity of 3-Hydroxy-3-Methilglutaryl-CoA Inhibitors
Cardiovascular & Hematological Agents in Medicinal Chemistry Vitamin D status in coronary artery disease: association with IL-35 and TGF-β1 and disease severity
Endocrine, Metabolic & Immune Disorders - Drug Targets Vaccination Against High Blood Pressure
Current Pharmaceutical Design Biological Nitration of Arachidonic Acid
Current Vascular Pharmacology Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function
Current Neuropharmacology Pregnancy-Associated Plasma Protein-A and its Role in Cardiovascular Disease. Biology, Experimental/Clinical Evidences and Potential Therapeutic Approaches
Current Vascular Pharmacology Neural Progenitors and HIV-1- Associated Central Nervous System Disease in Adults and Children
Current HIV Research Recent Patented Applications of Ion-Exchange Membranes in the Agrifood Sector
Recent Patents on Chemical Engineering The Effectiveness of Interventions to Address Health Inequalities During Pregnancy: A Review of Relevant Literature
Current Women`s Health Reviews Stenting Renal Artery Stenosis: What is the Fuss All About?
Reviews on Recent Clinical Trials Improved Lipid Target Level Attainment in Patients with Peripheral Artery Disease
Current Vascular Pharmacology Design and Development of a Novel Supportive Care Product for the Treatment of Sialorrhea in Parkinson’s Disease
Current Topics in Medicinal Chemistry Endothelial Progenitor Cells as a Therapeutic Approach for Intracerebral Hemorrhage
Current Pharmaceutical Design